Development of spliceosome-mediated RNA trans-splicing (SMaRT™) for the correction of inherited skin diseases

G. Dallinger, M. Puttaraju, L. G. Mitchell, K. B. Yancey, C. Yee, A. Klausegger, H. Hintner, Johann W. Bauer

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Gene therapy of large genes (e.g. plectin and collagen genes) is hampered by size limitations for insertions of the currently used viral vectors. To reduce the size of these insertions spliceosome-mediated RNA trans-splicing (SMaRT™), which provides intron-specific gene-correction at the pre-RNA level, can be an alternative approach. To test its applicability in skin gene therapy, SMaRT™ was used in the context of the 4003delTC mutation in the collagen XVII gene (COL17A1) causing generalized atrophic benign junctional epidermolysis bullosa. A β-galactosidase (β-gal) trans-splicing, assay system was established using intron 51 of COL17A1 as the target for trans-splicing. In this system, intron 51 is flanked by the 5′exon and the 3′exon of the β-gal gene, the latter containing two in-frame stop codons. Cotransfection of a pre-trans-splicing molecule consisting of the binding domain of intron 51 and the 3′exon of β-gal without the stop codons resulted in a 300-fold increase of β-gal activity compared to controls. A 2-3-fold increase in efficiency was obtained through an elongation of the binding domains. Replacement of the complete 3′end of the COL17A1 gene was shown using a collagen XVII mini-gene construct. The β-gal assay was used in human keratinocytes to evaluate the influence of a keratinocyte-specific spliceosome background. Reverse transcription polymerase chain reaction and β-gal activity assay showed functional correction of the stop-codons in cultured human keratinocytes and in an immortalized GABEB cell line harbouring the 4003delTC mutation. These results demonstrate that SMaRT™ is feasible in a keratinocyte-specific context and therefore may be applied in skin gene therapy.

Original languageEnglish (US)
Pages (from-to)37-46
Number of pages10
JournalExperimental Dermatology
Volume12
Issue number1
DOIs
StatePublished - Feb 2003

Fingerprint

Trans-Splicing
Spliceosomes
Skin Diseases
Skin
Genes
RNA
Keratinocytes
Gene therapy
Introns
Terminator Codon
Junctional Epidermolysis Bullosa
Genetic Therapy
Assays
Plectin
Galactosidases
Mutation
Polymerase chain reaction
Transcription
Reverse Transcription
Elongation

Keywords

  • Gene therapy
  • Junctional epidermolysis bullosa
  • Keratinocytes
  • RNA repair

ASJC Scopus subject areas

  • Dermatology

Cite this

Development of spliceosome-mediated RNA trans-splicing (SMaRT™) for the correction of inherited skin diseases. / Dallinger, G.; Puttaraju, M.; Mitchell, L. G.; Yancey, K. B.; Yee, C.; Klausegger, A.; Hintner, H.; Bauer, Johann W.

In: Experimental Dermatology, Vol. 12, No. 1, 02.2003, p. 37-46.

Research output: Contribution to journalArticle

Dallinger, G. ; Puttaraju, M. ; Mitchell, L. G. ; Yancey, K. B. ; Yee, C. ; Klausegger, A. ; Hintner, H. ; Bauer, Johann W. / Development of spliceosome-mediated RNA trans-splicing (SMaRT™) for the correction of inherited skin diseases. In: Experimental Dermatology. 2003 ; Vol. 12, No. 1. pp. 37-46.
@article{dc40d05bb725431680a64a34c952a2d4,
title = "Development of spliceosome-mediated RNA trans-splicing (SMaRT™) for the correction of inherited skin diseases",
abstract = "Gene therapy of large genes (e.g. plectin and collagen genes) is hampered by size limitations for insertions of the currently used viral vectors. To reduce the size of these insertions spliceosome-mediated RNA trans-splicing (SMaRT™), which provides intron-specific gene-correction at the pre-RNA level, can be an alternative approach. To test its applicability in skin gene therapy, SMaRT™ was used in the context of the 4003delTC mutation in the collagen XVII gene (COL17A1) causing generalized atrophic benign junctional epidermolysis bullosa. A β-galactosidase (β-gal) trans-splicing, assay system was established using intron 51 of COL17A1 as the target for trans-splicing. In this system, intron 51 is flanked by the 5′exon and the 3′exon of the β-gal gene, the latter containing two in-frame stop codons. Cotransfection of a pre-trans-splicing molecule consisting of the binding domain of intron 51 and the 3′exon of β-gal without the stop codons resulted in a 300-fold increase of β-gal activity compared to controls. A 2-3-fold increase in efficiency was obtained through an elongation of the binding domains. Replacement of the complete 3′end of the COL17A1 gene was shown using a collagen XVII mini-gene construct. The β-gal assay was used in human keratinocytes to evaluate the influence of a keratinocyte-specific spliceosome background. Reverse transcription polymerase chain reaction and β-gal activity assay showed functional correction of the stop-codons in cultured human keratinocytes and in an immortalized GABEB cell line harbouring the 4003delTC mutation. These results demonstrate that SMaRT™ is feasible in a keratinocyte-specific context and therefore may be applied in skin gene therapy.",
keywords = "Gene therapy, Junctional epidermolysis bullosa, Keratinocytes, RNA repair",
author = "G. Dallinger and M. Puttaraju and Mitchell, {L. G.} and Yancey, {K. B.} and C. Yee and A. Klausegger and H. Hintner and Bauer, {Johann W.}",
year = "2003",
month = "2",
doi = "10.1034/j.1600-0625.2003.120105.x",
language = "English (US)",
volume = "12",
pages = "37--46",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Development of spliceosome-mediated RNA trans-splicing (SMaRT™) for the correction of inherited skin diseases

AU - Dallinger, G.

AU - Puttaraju, M.

AU - Mitchell, L. G.

AU - Yancey, K. B.

AU - Yee, C.

AU - Klausegger, A.

AU - Hintner, H.

AU - Bauer, Johann W.

PY - 2003/2

Y1 - 2003/2

N2 - Gene therapy of large genes (e.g. plectin and collagen genes) is hampered by size limitations for insertions of the currently used viral vectors. To reduce the size of these insertions spliceosome-mediated RNA trans-splicing (SMaRT™), which provides intron-specific gene-correction at the pre-RNA level, can be an alternative approach. To test its applicability in skin gene therapy, SMaRT™ was used in the context of the 4003delTC mutation in the collagen XVII gene (COL17A1) causing generalized atrophic benign junctional epidermolysis bullosa. A β-galactosidase (β-gal) trans-splicing, assay system was established using intron 51 of COL17A1 as the target for trans-splicing. In this system, intron 51 is flanked by the 5′exon and the 3′exon of the β-gal gene, the latter containing two in-frame stop codons. Cotransfection of a pre-trans-splicing molecule consisting of the binding domain of intron 51 and the 3′exon of β-gal without the stop codons resulted in a 300-fold increase of β-gal activity compared to controls. A 2-3-fold increase in efficiency was obtained through an elongation of the binding domains. Replacement of the complete 3′end of the COL17A1 gene was shown using a collagen XVII mini-gene construct. The β-gal assay was used in human keratinocytes to evaluate the influence of a keratinocyte-specific spliceosome background. Reverse transcription polymerase chain reaction and β-gal activity assay showed functional correction of the stop-codons in cultured human keratinocytes and in an immortalized GABEB cell line harbouring the 4003delTC mutation. These results demonstrate that SMaRT™ is feasible in a keratinocyte-specific context and therefore may be applied in skin gene therapy.

AB - Gene therapy of large genes (e.g. plectin and collagen genes) is hampered by size limitations for insertions of the currently used viral vectors. To reduce the size of these insertions spliceosome-mediated RNA trans-splicing (SMaRT™), which provides intron-specific gene-correction at the pre-RNA level, can be an alternative approach. To test its applicability in skin gene therapy, SMaRT™ was used in the context of the 4003delTC mutation in the collagen XVII gene (COL17A1) causing generalized atrophic benign junctional epidermolysis bullosa. A β-galactosidase (β-gal) trans-splicing, assay system was established using intron 51 of COL17A1 as the target for trans-splicing. In this system, intron 51 is flanked by the 5′exon and the 3′exon of the β-gal gene, the latter containing two in-frame stop codons. Cotransfection of a pre-trans-splicing molecule consisting of the binding domain of intron 51 and the 3′exon of β-gal without the stop codons resulted in a 300-fold increase of β-gal activity compared to controls. A 2-3-fold increase in efficiency was obtained through an elongation of the binding domains. Replacement of the complete 3′end of the COL17A1 gene was shown using a collagen XVII mini-gene construct. The β-gal assay was used in human keratinocytes to evaluate the influence of a keratinocyte-specific spliceosome background. Reverse transcription polymerase chain reaction and β-gal activity assay showed functional correction of the stop-codons in cultured human keratinocytes and in an immortalized GABEB cell line harbouring the 4003delTC mutation. These results demonstrate that SMaRT™ is feasible in a keratinocyte-specific context and therefore may be applied in skin gene therapy.

KW - Gene therapy

KW - Junctional epidermolysis bullosa

KW - Keratinocytes

KW - RNA repair

UR - http://www.scopus.com/inward/record.url?scp=0043175257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0043175257&partnerID=8YFLogxK

U2 - 10.1034/j.1600-0625.2003.120105.x

DO - 10.1034/j.1600-0625.2003.120105.x

M3 - Article

C2 - 12631245

AN - SCOPUS:0043175257

VL - 12

SP - 37

EP - 46

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 1

ER -